However, despite treatment advances, 10–20% of PCa cases progress to an incurable stage known as castration‐resistant prostate cancer (CRPC).[6] CRPC often arises from mutations in the androgen receptor gene and the generation of splice variants, facilitating malignant PCa cell proliferation even under low androgen conditions.[7, 8] This stage presents a significant therapeutic challenge due to its resistance to conventional treatments. Here, AR is linked to posterior cortical atrophy.